Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Structural and Neurometabolic Correlates of Motor Neuron Function in ALS: A Multimodal fMRI-MRS-DTI-Texture Intersection Study
Neuromuscular and Clinical Neurophysiology (EMG)
P8 - Poster Session 8 (8:00 AM-9:00 AM)
1-005

Determine if impaired FC of the primary motor cortex (PMC) in ALS is associated with underlying structural damage to cortical motor neurons (cMNs).

 
ALS is a neurodegenerative disorder characterized by upper and lower motor neuron loss resulting in limb, speech and swallowing paralysis, respiratory deficits, and death within 3-5 years of diagnosis. MRI has revealed widespread alterations in cortical functional connectivity (FC), abnormal texture in the gray matter, reduced fractional anisotropy (FA) in the white matter, and altered neurochemical levels (reduced N-acetylaspartate [tNAA] and increased myo-Inositol [mI]). The contribution of structural and neurochemical changes to FC is unknown. We hypothesize that alterations in FC between brain regions in a no-task condition is explained by their underlying structural and neurochemical properties.
Fifty-nine patients with ALS and forty-six healthy controls (HC) were recruited from four Canadian centers as part of a nationwide study for the Canadian ALS Neuroimaging Consortium (CALSNIC). Multimodal MRI data (T1-texture, magnetic resonance spectroscopy, diffusion tensor imaging, and functional MRI) was used in statistical full factorial models to analyze the extent of alterations in FC, texture, microstructural white matter, and neurochemical levels within the PMC. Multivariate linear regression analyses were performed to examine whether any alterations in the microstructural and neurochemical properties explain the functional activation patterns of the cMNs.
Reduced FA and tNAA/Creatinine (Cr) in the PMC was observed in patients compared to HCs. However, there were no significant texture changes. Furthermore, the PMC exhibited an increase in FC with the superior parietal lobule and a decrease in FC with the middle frontal gyrus. These FC alterations were associated with reduced FA and tNAA/Cr values.

Underlying structural and neurochemical deficits of the PMC in ALS play an important role in explaining FC alterations.
Authors/Disclosures
Ojas Srivastava (University of Alberta Hospital)
PRESENTER 		Mr. Srivastava has nothing to disclose.
No disclosure on file
No disclosure on file
Angela L. Genge, MD (Mcgill University) Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AL-S Pharma. Dr. Genge has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Genge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Quralis. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Genge has received personal compensation in the range of $0-$499 for serving as a Consultant for WAVE. Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for eikonizo. Dr. Genge has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for rapa.
No disclosure on file
Lawrence Korngut, MD Dr. Korngut has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Korngut has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Korngut has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche.
Lorne H. Zinman, MD Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, MTP, AB Science, Cytokinetics, Amylyx. Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx.
Sanjay Kalra, MD (University of Alberta) The institution of Dr. Kalra has received research support from Brain Canada Foundation. The institution of Dr. Kalra has received research support from Biogen.